Effect of low-molecular-weight heparin combined with paclitaxel on the invasiveness and migration of nasopharyngeal carcinoma cellsin vitro

Abstract

Abstract: ObjectiveTo investigate the effect of low-molecular-weight heparin (LMWH) combined with paclitaxel (PTX) on the
invasiveness and migration of nasopharyngeal carcinoma cells and explore the molecular mechanisms. MethodsMTT assay
was used to detect the growth inhibition induced by LMWH and PTX in CNE1 and CNE2 cells. Wound healing assay and
Transwell migration assay were employed to assess the effects of the drugs on the cell migration, and Transwell invasion assay
was used to evaluate the cell invasiveness. The cellular expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor
of matrix metalloproteinase-1 (TIMP-1) were analyzed by Western blotting. ELISA was used to determine the expression of
heparanase (HPA) in the culture medium of the cells.ResultsMTT assay showed an obvious suppression of CNE1 and CNE2
cell proliferation in response to LMWH and PTX treatments. Treatment with 200 U·ml LMWH combined with 0.1μmol·L PTX
for 24 h resulted in the inhibition rates of migration of 66.70% and 70.53% in CNE1 and CNE2 cells, respectiuely significantly
higher than the rates in cells with PTX treatment alone. The combined treatment with LMWH and PTX for 24 h also caused a
significantly higher inhibition rate of cell invasion than LMWH and PTX alone. LMWH enhanced the down-regulation of
MMP-9 and HPA induced by PTX.ConclusionLMWH can enhance the inhibitory effect of PTX on the migration and invasion
of nasopharyngeal carcinoma cells, the mechanism of which may involve the down-regulation of MMP-9 and HPA expressions

References

［1］Zhou J, Xiao X, Yi H, et al. Upregulation of Gp96 correlates with the radiosensitivity and five-year survival rate of nasopharyngeal carcinoma［J］. ORL J Otorhinolaryngol Relat Spec, 2012, 74(3):164-71.
［2］Huang PY, Mai HQ, Luo DH, et al. Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma［J］. Ai Zheng, 2009, 28(10): 1033-42.
［3］Bossi P, Orlandi E, Bergamini C, et al. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locallyadvanced EBV-related nasopharyngeal cancer［J］. Ann Oncol, 2011,
22(11): 2495-500.
［4］Zhang W, Yang HC, Wang Q, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis［J］. Anticancer Res, 2011, 31(10): 3423-8.
［5］Hiro J, Inoue Y, Toiyama Y, et al. Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer［J］. Oncol Rep, 2010, 24(4): 1029-34.
［6］Mostafa E, Nasar MN, Rabie NA, et al. Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma［J］. J Egypt Natl Canc Inst, 2006, 18(4): 348-56.
［7］Phillips PG, Yalcin M, Cui H, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novelnon-anticoagulant low molecular weight heparin［J］. Anticancer Res, 2011, 31(2): 411-9.
［8］Dredge K, Hammond E, Handley P, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models［J］. Br J Cancer, 2011,104(4): 635-42.
［9］Chen Y, Chen Y, Huang L, et al. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma［J］. J Dermatol, 2012, 39(4): 339-43.
［10］Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngealcarcinoma［J］. Int J Radiat Oncol Biol Phys, 2006, 64(2): 374-81.
［11］Ahmad S, Ansari AA. Therapeutic roles of heparin anticoagulantsin cancer and related disorders ［J］. Med Chem, 2011, 7(5): 504-17.
［12］Canales JF, Ferguson JJ. Low-molecular-weight heparins: mechan-isms, trials, and role in contemporary interventional medicine［J］.Am J Cardiovasc Drugs, 2008, 8(1): 15-25.
［13］Niers TM, Klerk CP, Dinisio M, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models ［J］. Crit Rev Oncol Hematol, 2007, 61(3): 195-207.
［14］Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence［J］. Thromb Haemost, 2009,102(2): 258-67.
［15］Pandita D, Ahuja A, Velpandian T, et al. Characterization andin vitroassessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique［J］. Pharmazie, 2009, 64(5): 301-10.
［16］Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer［J］. JClin Oncol, 2009, 27(31): 5287-97.
［17］Lan YY, Hsiao JR, Chang KC, et al. Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9［J］. J Virol, 2012, 86(12): 6656-67.
［18］Groblewska M, Siewko M, Mroczko B, et al. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer［J］. Folia Histochem Cytobiol,2012, 50(1): 12-9.
［19］Farina AR, Cappabianca L, Desantis G, et al. Thioredoxin stimul-ates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrUm and promotes MMP-9 dependent invasion in humanMDA-MB-231 breast cancer cells［J］. FEBS Lett, 2011, 585(20):
3328-36.
［20］Teoh ML, Fitzgerald MP, Oberley LW, et al. Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion［J］. Cancer Res, 2009, 69(15): 6355-63.
［21］Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis ［J］. Int J Biochem Cell Biol, 2006, 38(12): 2018-39.
［22］Raman K, Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans［J］. Curr Chem Biol, 2010, 4(1): 20-31.